BACKGROUND: Racial/ethnic differences in shared decision making about cardiovascular risk-reduction therapy could affect health disparities. OBJECTIVE: To investigate whether patient race/ethnicity is associated with experiences discussing cardiovascular risk-reduction therapy with health care providers. SETTING: National sample of US adults identified by random-digit dialing. DESIGN: Cross-sectional survey conducted in November 2006 to May 2007. PARTICIPANTS: Among participants in the National Survey of Medical Decisions (DECISIONS), a nationally representative sample of English-speaking US adults aged 40 and older, the authors analyzed respondents who reported discussing hyperlipidemia or hypertension medications with a health care provider in the previous 2 years. MEASUREMENTS: In multivariate linear and logistic regressions adjusting for age, gender, income, insurance status, perceived health, and current therapy, they assessed the relation between race/ethnicity (black/Hispanic v. white) and decision making: knowledge, discussion of pros and cons of therapy, discussion of patient preference, who made the final decision, preferred involvement, and confidence in the decision. RESULTS: Of respondents who discussed high cholesterol (N = 738) or hypertension (N = 745) medications, 88% were white, 9% black, and 4% Hispanic. Minorities had lower knowledge scores than whites for hyperlipidemia (42% v. 52%, difference -10% [95% confidence interval (CI): 15, -5], P < 0.001), but not for hypertension. For hyperlipidemia, minorities were more likely than whites to report that the health care provider made the final decision for treatment (31.7% v. 12.3% whites, difference 19.4% [95% CI: 6.9, 33.1%], P < 0.01); this was not true for hypertension. LIMITATIONS: Possible limitations include the small percentage of minorities in the sample and potential recall bias. CONCLUSIONS: Minorities considering hyperlipidemia therapy may be less informed about and less involved in the final decision-making process.
BACKGROUND: Racial/ethnic differences in shared decision making about cardiovascular risk-reduction therapy could affect health disparities. OBJECTIVE: To investigate whether patient race/ethnicity is associated with experiences discussing cardiovascular risk-reduction therapy with health care providers. SETTING: National sample of US adults identified by random-digit dialing. DESIGN: Cross-sectional survey conducted in November 2006 to May 2007. PARTICIPANTS: Among participants in the National Survey of Medical Decisions (DECISIONS), a nationally representative sample of English-speaking US adults aged 40 and older, the authors analyzed respondents who reported discussing hyperlipidemia or hypertension medications with a health care provider in the previous 2 years. MEASUREMENTS: In multivariate linear and logistic regressions adjusting for age, gender, income, insurance status, perceived health, and current therapy, they assessed the relation between race/ethnicity (black/Hispanic v. white) and decision making: knowledge, discussion of pros and cons of therapy, discussion of patient preference, who made the final decision, preferred involvement, and confidence in the decision. RESULTS: Of respondents who discussed high cholesterol (N = 738) or hypertension (N = 745) medications, 88% were white, 9% black, and 4% Hispanic. Minorities had lower knowledge scores than whites for hyperlipidemia (42% v. 52%, difference -10% [95% confidence interval (CI): 15, -5], P < 0.001), but not for hypertension. For hyperlipidemia, minorities were more likely than whites to report that the health care provider made the final decision for treatment (31.7% v. 12.3% whites, difference 19.4% [95% CI: 6.9, 33.1%], P < 0.01); this was not true for hypertension. LIMITATIONS: Possible limitations include the small percentage of minorities in the sample and potential recall bias. CONCLUSIONS: Minorities considering hyperlipidemia therapy may be less informed about and less involved in the final decision-making process.
Authors: Victor Okunrintemi; Rohan Khera; Erica S Spatz; Joseph A Salami; Javier Valero-Elizondo; Haider J Warraich; Salim S Virani; Ron Blankstein; Michael J Blaha; Timothy M Pawlik; Kumar Dharmarajan; Harlan M Krumholz; Khurram Nasir Journal: J Gen Intern Med Date: 2019-02-19 Impact factor: 5.128
Authors: Monica E Peek; Fanny Y Lopez; H Sharif Williams; Lucy J Xu; Moira C McNulty; M Ellen Acree; John A Schneider Journal: J Gen Intern Med Date: 2016-06 Impact factor: 5.128
Authors: Stephanie Bi; Kathryn E Gunter; Fanny Y López; Seeba Anam; Judy Y Tan; Danielle J Polin; Justin L Jia; Lucy J Xu; Neda Laiteerapong; Mai T Pho; Karen E Kim; Marshall H Chin Journal: Med Care Date: 2019-12 Impact factor: 2.983
Authors: Nynikka R Palmer; Steven E Gregorich; Jennifer Livaudais-Toman; Jane Jih; Celia P Kaplan Journal: J Racial Ethn Health Disparities Date: 2018-03-07